Abstract
PC-904, a new semisynthetic penicillin, was administered to 30 episodes of the infections in 21 patients of acute leukemia. Fourteen episodes (46. 7%) responded to this antibiotic and response rate was TIM dependent on the number of circulating polymorphonuclear neutrophils. PC-904 was most effective against Pseudomonas infections, including 2 cases of Pseudomonas septicemia with dramatic response after having failed to respond to either Carbenicillin or Sulbenicillin, or both. No significant side effect was observed with PC-904.
